Introduction
Hepatic veno-occlusive disease (VOD) is among a spectrum of organ injury syndromes that occurs after the high-dose chemotherapy employed with hematopoietic stem cell transplantation. 1 VOD incidence varies but generally occurs in about 10% of patients after allogeneic stem cell transplantation employing myeloablative conditioning regimens. [2] [3] [4] The incidence of VOD is lower after autologous SCT and reduced intensity conditioning transplantation. 3, 5 Prognosis depends on the extent of hepatic injury, liver dysfunction and presence of multiorgan failure (MOF). 2, 3, 6, 7 Severe VOD is associated with an all-cause mortality of over 90% by D þ 100 post-SCT. 2, 3, 7 Standard therapy for VOD in North America is supportive. Clinical trials using systemic anticoagulants or thrombolytics have been associated with excessive bleeding complications, and have not improved survival. Defibrotide (DF), a polydisperse oligonucleotide mixture that has protective effects on vascular endothelium, has demonstrated encouraging responses with little toxicity in multicenter phase I/II trials. [8] [9] [10] [11] Recent studies have also demonstrated that DF is an effective agent for VOD prophylaxis after transplantation in patients at high risk for this complication.
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Pathogenesis
Injury to sinusoidal endothelial cells and hepatocytes by high-dose alkylating chemotherapy agents appear to be the primary event in the pathogenesis of VOD. [15] [16] [17] [18] A number of markers of endothelial injury and adhesion molecules are upregulated in patients with VOD. These include plasma thrombomodulin (TM), P-and E-selectins, tissue factor pathway inhibitor (TFPI), soluble tissue factor (sTF) and plasminogen activator inhibitor (PAI-1). [19] [20] [21] [22] [23] Increased serum levels of PAI-1 is both a diagnostic and prognostic marker for VOD. [21] [22] [23] [24] [25] [26] In vitro studies show that endothelial PAI-1 production is triggered by transforming growth factor beta (TGF-b) released from activated platelets, 27 and elevated plasma TGF-b levels in patients pretransplant have been associated with the development of hepatic VOD. 28 Murine models have also demonstrated that decreased nitric oxide (NO) production contributes to the development of VOD. 29 It is noteworthy that NO is pivotal in the prevention of ischemic/reperfusion injury in the liver, and is a potent suppressor of PAI-1 production. 30 Tiplaxtinin, an active PAI-1 inhibitor, has been shown to prevent hepatic venous injury in murine models, and PAI-1 null (À/À) knockout mice are protected against hepatic vein thrombosis mediated by chronic NO synthase inhibition. 31 Based on recent studies suggesting that sinusoidal endothelial cells are key initial sites of injury, especially in gemtuzumab ozogamicin (Mylotarg, Wyeth Pharmaceuticals, Philadelphia, PA, USA) associated VOD, the term 'sinusoidal obstruction syndrome' (SOS) is sometimes used as an alternative to the established terminology of VOD. 32 Further clinico-pathologic validation of this concept is warranted because sinusoidal obstruction is not a prominent early feature in all cases of human VOD. In the interim, a preferred terminology that has been coined is VOD/SOS. 33 
Risk factors for VOD
The incidence and severity of VOD can be influenced by differences in pretransplant patient characteristics, transplant conditioning regimens, GVHD prophylaxis regimens and source of graft (allogeneic vs autologous). 3, [34] [35] [36] Recognized pretransplant risk factors for the development of VOD include older transplant recipient age, poor performance status, female gender, donor-recipient HLA disparity, advanced malignancy, prior abdominal radiation, second myeloablative transplant, reduced pulmonary diffusion capacity (DLCO) and prior liver disease including elevated AST prior to conditioning or preexisting cirrhosis. 3, 34, 37, 38 In the pediatric literature, younger age at transplant (o6.5 years) also appears to be a risk factor for the development of hepatic VOD. 39 The type and intensity of the transplant conditioning regimen is probably the greatest determining factor of risk for developing severe VOD. VOD risk increases with TBI dose, radiation dose rate and dose of BU. 3, 6 A randomized study and a large IBMTR analysis have both shown a higher incidence of VOD in patients receiving BU/CY compared to cyclophosphamide and TBI (CY/TBI). 35, 40 High plasma levels of BU or the metabolites of cyclophosphamide are associated with an increased risk of VOD. 18, 41, 42 VOD occurs less frequently when targeted BU dosing or intravenous BU (Busulfex, PDL BioPharma, Fremont, CA, USA) administration is employed. 43, 44 Metabolites of CY have also been implicated in the development of VOD after SCT. 18, 42 However, a recent analysis in patients receiving targeted Bu/CY conditioning demonstrated striking interpatient variability in levels of cyclophosphamide and its metabolites, and no correlation between exposure of cyclophosphamide and its metabolites to development of VOD. 45 Prior exposure to gemtuzumab ozogamicin (Mylotarg) is increasingly recognized as a significant pretransplant risk factor for the development of severe VOD after SCT. In a retrospective analysis of 62 patients who received gemtuzumab ozogamicin and subsequently underwent allogeneic myeloablative SCT, the incidence of VOD was 64%, and the risk of VOD was greatest among those patients who had received gemtuzumab ozogamicin within 3.5 months of SCT. 46 Increased incidence of VOD in association with gemtuzumab ozogamicin pre-SCT have also been reported in the pediatric literature, 47 and in a recently published report from the Research on Adverse Drug Events and Reports (RADAR) project. 48 GVHD prophylaxis regimens for allogeneic transplantation also affect the risk of VOD. A low incidence of VOD has been reported in patients receiving T cell-depleted grafts compared to calcineurin inhibitor plus methotrexate based regimens. [49] [50] [51] The fact that the GVHD prophylaxis combination of sirolimus and tacrolimus is associated with an increased incidence of thrombotic microangiopathy after transplant has raised some speculation as to whether it would predispose to VOD as well. 52, 53 Defibrotide DF, a polydisperse mixture of single-stranded oligonucleotide with local antithrombotic, anti-ischemic and antiinflammatory activity, has shown great promise as therapy in severe VOD in clinical trials. DF appears to modulate endothelial cell injury without enhancing systemic bleeding and protects sinusoidal endothelium without compromising the antitumor effects of cytotoxic therapy. 54 DF binds to vascular endothelium via adenosine receptors A1 and A2, which are part of the growing family of nucleotide receptors involved in endothelial cell regulation and response to injury. 55, 56 DF modulates platelet activity by increasing levels of endogenous prostaglandins (PGI-2 and E-2) and TM and promotes fibrinolysis via upregulation of TFPI and tissue plasminogen activator (tPA).
57-60 DF also decreases thrombin generation and reduces circulating levels of PAI-1. 57, 61, 62 Preclinical studies demonstrate that DF has profibrinolytic activity and prevents fibrin deposition with selective activity in small vessels. Studies using human-derived endotoxin-damaged endothelium have shown selective protective effects of DF for microvascular, but not macrovascular, endothelium.
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Defibrotide as treatment of hepatic VOD A summary of reported studies using DF in the treatment of patients with VOD after SCT is presented in Table 1 . The first trial using DF in patients with VOD post-SCT was conducted in the United States from 1995 to 1997. In this compassionate use study, DF was administered to 19 consecutive SCT patients with clinically established severe VOD defined by 430% risk on the Bearman model and/or the presence of MOF. 65 Patient age ranged from 4 to 58 years (median 35), with 4 patients aged less than 18 years. At the initiation of treatment, the median bilirubin was 22.3 mg/dl. All had evidence of MOF, with encephalopathy in 8 patients, renal insufficiency in 12 (with 5 dialysisdependent) and oxygen requirement, including ventilator dependence, in 14 patients. Ascites was present in all but one patient. Treatment with DF was initiated at a median of 6 days after the diagnosis of VOD. DF was administered intravenously in doses ranging from 5 to 60 mg/kg per day for a planned minimum course of 14 days. Response to DF therapy was demonstrated by resolution of VOD (bilirubin o2 mg/dl with improvement in other VOD-related symptoms and signs) in 8/19 patients (42%) and 6/19 (32%) survived past D þ 100. Most importantly, this favorable response and survival was seen in the absence of toxicity or severe hemorrhage. In light of the historical data at the time showing predicted 100-day survival of comparable patients to be less than 10%, the observed response rate of 42 and 32% survival rate at D þ 100 were compelling.
These favorable results were confirmed in a subsequent European compassionate use trial by Chopra et al. 9 In this study of 40 patients with established VOD treated with DF in 19 European transplant centers, 22 (55%) achieved a complete response and 17 (43%) survived to D þ 100. Among the 28 patients in this series who were considered to have severe VOD, characterized by the presence of MOF, the complete response rate after DF therapy was 36%.
As an extension of the American compassionate use study, eight US transplantation centers formed a working group and enrolled 69 more patients following the original eligibility criteria and treatment protocol. In this combined cohort of 88 patients, 36% (32/88) of patients achieved CR (95% confidence interval: 26 and 47%) and 35% (31/88) survived beyond D þ 100 (95% CI: 25 and 46%). 10 This result is better than expected given the extremely compromised condition of these patients, almost all of whom had MOF. Importantly, in responding patients, no chronic liver dysfunction or recurrent VOD was reported during longterm follow-up. Continuous variables associated with better outcome in this study included mean decrease in creatinine and PAI-1 levels during DF therapy. The observation that decreases in both actual and mean serum creatinine predicted better outcome is interesting and may reflect the favorable renovascular effects associated with DF treatment in other disease states. 69 To determine the effective dose of DF for use in future studies of patients with severe VOD, a large multicenter, prospective phase II randomized study has been recently completed testing both 25 mg/kg per day (arm A) and 40 mg/kg per day (arm B), and the final results were recently reported at the meeting of the American Society of Hematology in 2006. 68 The clinical diagnosis of VOD was defined by Baltimore criteria and severity was determined by X30% risk on the Bearman model 70 and/or the presence of MOF. Treatment was planned for at least 14 days and patients receiving o3 days of therapy were inevaluable for response but were evaluable for toxicity and survival. A total of 150 patients were treated, 75 on each arm and 99% had evidence of MOF. Median duration of DF therapy was 19 days (range 1-82). Of 150 patients treated, 141 were evaluable for response: 65 patients achieved CR (46%) and 62 survived to D þ 100 (41%), including patients with prior dialysis or ventilator dependence. No significant difference in CR and D þ 100 survival was found between the two doses, although in pediatric patients receiving 25 mg/kg per day, CR and D þ 100 survival was superior at 67% (P ¼ 0.06). Toxicity was limited, but there was a statistically nonsignificant increase in attributable Grade 3/4 events, including bleeding and hypotension, in patients getting 40 mg/kg per day. Endothelial cell stress marker studies have shown a reduction in median levels of PAI-1 and nitric oxide, and an increase in Protein C in patients achieving CR (Po0.05). In contrast, median serum TM, TFPI and sTF levels increased in patients without response (Po0.05). Because no difference in efficacy was observed between the two dose levels, and there was a trend toward more toxicity with the higher dose, the lower dose of 25 mg/kg per day has been selected for future studies. A pivotal phase III trial using this dose DF as therapy for severe VOD is currently underway at 36 transplant centers across North America and Israel, using a historical control methodology.
Encouraging responses to DF have also been reported in the treatment of children with severe VOD. In a retrospective analysis of 45 VOD patients aged 0.2-20 years treated with DF, 34 (76%) achieved a complete response, defined as resolution of VOD and MOF-related symptoms together with normalization of bilirubin to less than 2 mg/ dl. 11 The CR rate was 50% in the subset of 22 patients with severe VOD. Interestingly, the authors reported that the average DF dose in the CR patients were significantly higher than in the nonresponders: 45 vs 27 mg/kg per day, and there was no apparent dose-related increase in toxicity. These results suggest that in children and adolescents, higher doses of DF may be beneficial. In a more recent Canadian single-center report of 14 children treated with DF for VOD after SCT, 9 (60%) had resolution of VOD, and the D þ 100 survival was 79%. 67 Defibrotide as prophylaxis for hepatic VOD Encouraging results with DF as treatment have also spawned interest into its use in the prophylaxis setting. To date, the published literature on DF as VOD prophylaxis is restricted to smaller retrospectively controlled studies, as summarized in Table 2 . In one series of 52 allogeneic myeloablative PBSC/BMT patients given DF þ low-dose heparin as VOD prophylaxis, none (0%) developed VOD (defined by Baltimore criteria) compared to 10 cases in historical control cohort of 52 patients who received heparin alone. 12 Furthermore, the maximum level of total bilirubin up to D þ 100 and the percentage of patients with a total bilirubin 450 mmol/l were significantly lower in the DF-treated group. In a different series of 58 patients who received DF alone as VOD prophylaxis after allogeneic SCT, no cases of VOD meeting the Baltimore criteria were reported. 14 However, approximately half of the patients in this series actually received reduced intensity conditioning, and their risk for developing VOD was likely to be lower at baseline, although, like the prior study, comparison to historical control data in similar patient cohorts was shown to be highly favorable. Encouraging results with DF as VOD prophylaxis have also been reported in a case series of high VOD risk transplant recipients previously exposed to gemtuzumab ozogamicin, 71 and in children transplanted for infantile osteopetrosis. 13 While the results of these various studies are exciting, they must be interpreted with caution given their retrospective nature and limited sample size. Definitive conclusions regarding the efficacy of DF in the prophylaxis setting should await the results of the prospective randomized trials.
Other therapeutic agents in VOD
Tissue plasminogen activator Because micro-thromboses and fibrin deposition in hepatic central venules are hallmark features in VOD, many investigational efforts have focused around the use of systemic anticoagulants and more potent thrombolytics. There have been numerous reports in the literature of patients treated with tPA, with or without heparin, but only a few series have included more than 10 patients (Table 3 ). In the largest of these studies involving 42 patients with established VOD treated with tPA and unfractionated heparin, 12 (29%) had a clinical improvement with at least a 50% reduction in pre-treatment bilirubin. However, overall survival was poor and no patients with MOF responded. Furthermore, 10 patients (24%) developed severe bleeding attributable to tPA and a significant number proved fatal. 73 Based on these results, the investigators concluded that tPA with or without heparin should not be administered as treatment in VOD patients with MOF, and should only be considered as part of a clinical trial.
Antithrombin III and prostaglandin E1
Based on findings that antithrombin III (ATIII) confers a protective effect on vascular endothelium and ATIII levels are decreased in patients with VOD, a number of trials and case studies have tested whether ATIII has activity in VOD without causing bleeding diatheses. [86] [87] [88] However, concordant with prior studies in adults, a recent large pediatric transplant trial in which 91 children received preemptive ATIII replacement (ATIII given when plasma ATIII activity p70%) demonstrated that ATIII administration did not reduce the incidence of VOD compared to the control group of 71 children who received no VOD prophylaxis. 89 Prostaglandin E1 (PGE1) is a vasodilator with a cytoprotective effect on endothelium as well as being an inhibitor of platelet aggregation with prothrombolytic activity. 90 Successful treatment of VOD using PGE1 combined with low-dose heparin was reported in one small pediatric series. 91 Unfortunately, a larger prophylactic trial using PGE1 was complicated by excessive toxicity and no benefit. 92 Until the results of larger prospective studies are performed, use of either PGE1 or ATIII in the prophylaxis or treatment setting for VOD cannot be endorsed outside of the clinical trial setting.
Low-dose heparin and low molecular weight heparins Anticoagulation with low-dose heparin by continuous infusion, alone or in combination with other agents, has been evaluated as VOD prophylaxis in a number of clinical trials. While a single randomized study reported a benefit for low-dose continuous heparin prophylaxis, 93 other uncontrolled studies have shown that low-dose heparin was ineffective and/or dangerous, primarily due to an increased risk of hemorrhage. 3, 94, 95 Low-molecular-weight heparins seem to be relatively safe and may have some effect in the prevention of VOD, 82,96-100 but well-designed, multicenter randomized studies are needed to confirm these preliminary results.
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA), a hydrophilic nonhepatotoxic bile acid, has been studied in a number of randomized placebo-controlled prospective trials as a prophylaxis for VOD. While two randomized trials, including a multicenter study from Japan, demonstrated a statistically benefit for UDCA in patients at high risk of VOD, 101-103 a larger randomized study by the Nordic Bone Marrow Transplantation group failed to show a significant reduction in VOD incidence. 104 However, the UDCA patients in this trial did experience significantly fewer hepatic complications, especially liver GVHD, and enjoyed improved overall survival compared to the control arm. Taken together, these studies suggest a possible role for UDCA in the prevention of VOD and other hepatic complications after myeloablative allogeneic transplantation.
Nonpharmacologic interventions in VOD
Liver transplantation has led to clinical improvement of some patients with VOD, but this approach is limited by the availability of organs, perioperative complications of MOF, and liver graft rejection. 105 Transjugular intrahepatic porto-systemic shunts (TIPS) have also been tested as a therapeutic strategy to relieve portal hypertension in VOD patients after SCT. Available data suggest that while portal hypertension and ascites improve after TIPS, long-term efficacy and overall survival in VOD patients undergoing this procedure remain poor. 106, 107 Charcoal hemofiltration intended to adsorb bilirubin and protein bound toxins from the circulation has been reported to be successful in two patients, 108 but larger studies evaluating this approach are needed.
Future directions
Despite the promise of emerging therapies such as DF, VOD remains a much feared transplant complication associated with dismal prognosis. Risk stratification of patients before SCT will continue to be key for minimizing severe VOD and improving transplant outcome. For example, improved understanding of the risk factors for VOD will enable transplant physicians to offer patients at high risk a reduced intensity conditioning regimen, or T-cell depletion to minimize their risk for transplant mortality. For patients undergoing myeloablative SCT who are at increased risk for VOD, use of UDCA may be reasonable since it is associated with reduced hepatic complications (specifically hepatic GVHD) and better survival after SCT in a randomized trial, 104 although its efficacy as a prophylaxis agent against VOD remains debatable. Targeted dosing of BU and pharmacokinetic monitoring of CY and its metabolites could also be an effective method for reducing the risk of VOD. However, the feasibility of such a monitoring approach could be an issue among smaller transplant centers.
As PAI-1 is now recognized to be associated with the pathogenesis of VOD, laboratory measurement of plasma PAI-1 is coming into clinical practice. Serial monitoring of blood PAI-1 levels peritransplant should offer a new diagnostic, and potential prognostic tool for this disease. Patients with rising PAI-1 levels could potentially benefit from earlier clinical intervention with agents such as DF that could in turn curtail the development of severe VOD/MOF.
For patients who develop significant VOD, DF has emerged as an effective and safe treatment option, whereas Despite the encouraging responses observed with DF in clinical trials to date, there remains room for improvement both in terms of response rate and D þ 100 survival, especially in severe disease. Efforts to enhance effective therapy for VOD in the future are needed. As we better understand the pathogenesis of VOD, newer therapies targeting different endothelial injury response and platelet aggregation pathways can be used rationally in combination with DF to improve VOD outcome. For example, agents such as tiplaxtinin that inhibit PAI-1, or phosphodiesterase-5 inhibitors which potentiate nitric oxide effects on the vascular endothelium and reduce platelet aggregation may justify study in the clinical setting as part of a combination approach. Other treatment strategies with established safety profiles such as antithrombin III and Nacetylcysteine may also be worthy of further investigation, again likely best as part of combinations with DF. A similar approach in prophylaxis is warranted, including agents such as UDCA and perhaps low molecular weight heparin, although for the latter, care regarding bleeding risk remains a priority.
